183 related articles for article (PubMed ID: 38610029)
1. Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology.
Lin K; Xia B; Wang X; He X; Zhou M; Lin Y; Qiao Y; Li R; Chen Q; Li Y; Feng J; Chen T; Chen C; Li X; Zhang H; Lu L; Liu B; Zhang X
J Transl Med; 2024 Apr; 22(1):349. PubMed ID: 38610029
[TBL] [Abstract][Full Text] [Related]
2. Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment.
Xia B; Lin K; Wang X; Chen F; Zhou M; Li Y; Lin Y; Qiao Y; Li R; Zhang W; He X; Zou F; Li L; Lu L; Chen C; Li W; Zhang H; Liu B
Mol Ther Oncolytics; 2023 Sep; 30():86-102. PubMed ID: 37593111
[TBL] [Abstract][Full Text] [Related]
3. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy.
Lu LL; Xiao SX; Lin ZY; Bai JJ; Li W; Song ZQ; Zhou YH; Lu B; Wu WZ
Cell Biol Toxicol; 2023 Dec; 39(6):3101-3119. PubMed ID: 37853185
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
5. Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC.
Kolluri A; Li D; Li N; Duan Z; Roberts LR; Ho M
Hepatol Commun; 2023 Feb; 7(2):e0022. PubMed ID: 36691969
[TBL] [Abstract][Full Text] [Related]
6. Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells.
Wang H; Wang L; Li Y; Li G; Zhang X; Jiang D; Zhang Y; Liu L; Chu Y; Xu G
Cancer Cell Int; 2021 Aug; 21(1):450. PubMed ID: 34429118
[TBL] [Abstract][Full Text] [Related]
7. The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy.
Guizhen Z; Guanchang J; Liwen L; Huifen W; Zhigang R; Ranran S; Zujiang Y
Front Endocrinol (Lausanne); 2022; 13():918869. PubMed ID: 36093115
[TBL] [Abstract][Full Text] [Related]
8. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
[TBL] [Abstract][Full Text] [Related]
9. Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies.
Temple WC; Nix MA; Naik A; Izgutdina A; Huang BJ; Wicaksono G; Phojanakong P; Serrano JAC; Young EP; Ramos E; Salangsang F; Steri V; Xirenayi S; Hermiston M; Logan AC; Stieglitz E; Wiita AP
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007238
[TBL] [Abstract][Full Text] [Related]
10. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma.
Yang C; You J; Pan Q; Tang Y; Cai L; Huang Y; Gu J; Wang Y; Yang X; Du Y; Ouyang D; Chen H; Zhong H; Li Y; Yang J; Han Y; Sun F; Chen Y; Wang Q; Weng D; Liu Z; Xiang T; Xia J
BMC Med; 2023 Aug; 21(1):327. PubMed ID: 37635247
[TBL] [Abstract][Full Text] [Related]
12. FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma.
Sullivan PM; Kumar R; Li W; Hoglund V; Wang L; Zhang Y; Shi M; Beak D; Cheuk A; Jensen MC; Khan J; Dimitrov DS; Orentas RJ
Mol Cancer Ther; 2022 Oct; 21(10):1608-1621. PubMed ID: 35877472
[TBL] [Abstract][Full Text] [Related]
13. Identification of nanobodies against hepatocellular carcinoma marker glypican-3.
Wang W; Xu C; Wang H; Jiang C
Mol Immunol; 2021 Mar; 131():13-22. PubMed ID: 33453658
[TBL] [Abstract][Full Text] [Related]
14. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M
Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
[TBL] [Abstract][Full Text] [Related]
15. Nanobody-based CAR T cells targeting intracellular tumor antigens.
Li H; Zhong D; Luo H; Shi W; Xie S; Qiang H; Zhu L; Gao L; Liu J; Sun S; Ding Z; Yang X; Lu X
Biomed Pharmacother; 2022 Dec; 156():113919. PubMed ID: 36411612
[TBL] [Abstract][Full Text] [Related]
16. Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment.
Ma W; Zhu D; Li J; Chen X; Xie W; Jiang X; Wu L; Wang G; Xiao Y; Liu Z; Wang F; Li A; Shao D; Dong W; Liu W; Yuan Y
Theranostics; 2020; 10(3):1281-1295. PubMed ID: 31938065
[No Abstract] [Full Text] [Related]
17. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
[TBL] [Abstract][Full Text] [Related]
18. CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models.
Timpanaro A; Piccand C; Dzhumashev D; Anton-Joseph S; Robbi A; Moser J; Rössler J; Bernasconi M
J Exp Clin Cancer Res; 2023 Nov; 42(1):293. PubMed ID: 37924157
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?
Aggeletopoulou I; Kalafateli M; Triantos C
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473878
[TBL] [Abstract][Full Text] [Related]
20. Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library.
Yan J; Wang P; Zhu M; Li G; Romão E; Xiong S; Wan Y
J Nanobiotechnology; 2015 May; 13():33. PubMed ID: 25944262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
